Department of Nephrology, Children's Hospital of Nanjing Medical University, Nanjing, China.
Department of Nephrology, Children's Hospital of Nanjing Medical University, Nanjing, China; Nanjing Key Laboratory of Pediatrics, Children's Hospital of Nanjing Medical University, Nanjing, China; Jiangsu Key Laboratory of Pediatrics, Nanjing Medical University, Nanjing, China.
Biomol Biomed. 2023 May 1;23(3):376-391. doi: 10.17305/bb.2022.8534.
Inflammation contributes to the pathogenesis of several diseases. Fenofibrate, known as a peroxisome proliferator-activated receptor - α (PPAR-α) agonist, is a classic drug for treating hyperlipidemia. In addition to its lipid-lowering effect, fenofibrate has also been reported to exert anti-inflammatory effects with complicated underlying mechanisms of action. In general, the anti-inflammatory effect of fenofibrate is secondary to its lipid-lowering effect, especially for the inflammation caused by hyperlipidemia in the circulatory system. Some anti-inflammatory actions may also come from its regulatory effects on intracellular lipid metabolism by activating PPAR-α. In addition, some roles in anti-inflammation might be mediated by its direct regulation of inflammatory signaling pathways. In order to understand anti-inflammatory activities and the underlying mechanisms of fenofibrate action in disease better, we herein reviewed and discussed the anti-inflammatory roles and its subserving mechanisms in various diseases of different organ systems. Thus, this review offers insights into the optimal use of fenofibrate in the clinical setting.
炎症是多种疾病发病机制的重要组成部分。非诺贝特作为过氧化物酶体增殖物激活受体-α（PPAR-α）激动剂，是治疗高脂血症的经典药物。除了降脂作用外，非诺贝特还具有抗炎作用，其作用机制复杂。一般来说，非诺贝特的抗炎作用继发于其降脂作用，尤其是对循环系统中由高血脂引起的炎症。一些抗炎作用可能也来自于通过激活 PPAR-α 对细胞内脂质代谢的调节作用。此外，一些抗炎作用可能是通过其对炎症信号通路的直接调节来介导的。为了更好地了解非诺贝特在疾病中的抗炎活性及其作用机制，我们在此综述并讨论了非诺贝特在不同器官系统的各种疾病中的抗炎作用及其相关机制。因此，本综述为非诺贝特在临床中的合理应用提供了参考。
